Attorney's Docket No.: 14875-137US1 / C1-A0210Y1P-US

Applicant: Kodama et al.
Serial No.: Unassigned
Filed: Herewith
Page: 7 of 11

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## **Listing of Claims**:

- 1. (Original) A method for producing an antibody that recognizes a target antigen, wherein the method comprises the steps of:
- i) immunizing a non-human animal that has immunotolerance to a background antigen comprised in an immunogen, wherein the immunogen comprises both the target antigen and the background antigen; and
  - ii) obtaining an antibody against the target antigen, or a gene encoding the antibody.
  - 2. (Original) The method of claim 1, wherein immunotolerance is induced artificially.
- 3. (Original) The method of claim 1, wherein the non-human animal is a transgenic non-human animal.
- 4. (Original) A method for producing an antibody against a target antigen, wherein the method comprises the steps of:
  - (a) preparing an immunogen comprising the target antigen and a background antigen;
- (b) producing a transgenic non-human animal comprising a gene expressibly encoding the background antigen;
  - (c) administering the immunogen of (a) to the transgenic non-human animal of (b); and
- (d) isolating the antibody against the target antigen from the transgenic non-human animal.

Attorney's Docket No.: 14875-137US1 / C1-A0210Y1P-US

Applicant: Kodama et al.
Serial No.: Unassigned
Filed: Herewith
Page: 8 of 11

5. (Original) The method of claim 4, wherein the immunogen is a virus particle or a part thereof.

- 6. (Original) The method of claim 5, wherein the virus is a baculovirus.
- 7. (Original) The method of claim 4, wherein the target antigen is a membrane protein.
- 8. (Original) The method of claim 6, wherein the background antigen is gp64.
- 9. (Original) The method of claim 4, wherein the non-human animal is a mouse.
- 10. (Currently Amended) An antibody that is produced by the method of any one of claims 1 to 9 claim 1.
- 11. (Original) A chimeric antibody between a non-human animal and human, or a humanized antibody, produced using the antibody of claim 10.
- 12. (Original) A transgenic non-human animal, into which a gene encoding a viral envelope protein is introduced.
- 13. (Original) The transgenic non-human animal of claim 12, wherein the virus is a baculovirus.
- 14. (Original) The non-human animal of claim 13, wherein the viral envelope protein is gp64.
- 15. (Original) The non-human animal of claim 12, wherein the non-human animal is a mouse.

Applicant: Kodama et al. Attorney's Docket No.: 14875-137US1 / C1-A0210Y1P-US

Serial No.: Unassigned
Filed: Herewith
Page: 9 of 11

16. (Original) The non-human animal of claim 12, for use in producing an antibody against an antigen comprising a viral protein.

- 17. (Original) A method for producing a non-human immunized animal, wherein the method comprises the step of producing a transgenic non-human animal into which a gene encoding a background antigen is introduced.
- 18. (Original) A non-human immunized animal for obtaining an antibody against a target antigen comprising a background antigen, wherein the animal is produced by the method of claim 17.
- 19. (Original) A method for producing an antibody against PepT1, wherein the method comprises the steps of:
- (a) preparing a baculovirus that expressibly comprises a DNA which encodes PepT1 or a fragment thereof;
- (b) infecting a host cell with the baculovirus of (a) to obtain a budding virus that expresses PepT1 or a fragment thereof;
- (c) producing a transgenic non-human animal that expressibly comprises a gene encoding a baculovirus membrane protein gp64;
- (d) immunizing the transgenic non-human animal of (c) with a fraction comprising the budding virus of (b) or PepT1 or its fragment; and
  - (e) recovering the antibody-recognizing PepT1 from the immunized animal.
  - 20. (New) An antibody that is produced by the method of claim 4.